Avoro Capital Advisors
Crossover fundNew York · Seed–Series A · 22 people tracked
Find your way into Avoro Capital Advisors
814 people in our graph share verified history with the Avoro Capital Advisors team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Avoro Capital Advisors seeks scientific breakthroughs with the potential to address unmet medical needs, driven by intellectual curiosity. The firm aims to identify unique or mispriced investment opportunities, analyzing complex situations and supporting companies with both financial and intellectual resources across the lifecycle of an investment. It emphasizes disciplined risk management, evaluating macro and company-specific risks, and may employ tactical and fundamental hedges within its portfolio construction while carefully weighing position sizing and liquidity considerations.
Source: firm website, verified Sep 15, 2026.
Team · 22 people
from the firm's website & public directories
What they invest in
from 61 of 76 portfolio companiesBiotech ×59Healthtech ×45Medical Devices ×22Deep Tech ×10Digital Health ×4AI & Machine Learning ×3Longevity ×2Cloud Computing ×1
HQs:United States×39Switzerland×1Denmark×1United Kingdom×1Netherlands×1
Who they back
founder profiles across 22 portfolio companiesFounding team size:solo founder×152 founders×43 founders×14+ founders×2
Where their founders studiedfrom 18 founders with education data
Harvard University ×3University of California, Berkeley ×3Columbia University ×2Harvard Medical School ×2Imperial College London ×2Princeton University ×2
What their founders studiedfrom 18 founders with field-of-study data
Chemistry ×8Life Sciences ×8Engineering ×2Finance & Accounting ×2Medicine ×2
Where their founders worked beforefrom 20 founders with career history
Atlas Venture ×3GNF ×2
Investments · 76 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22022 · 12021 · 42020 · 12018 · 22017 · 52015 · 42014 · 32012 · 22010 · 126 dated
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
BiotechHealthtechMedical DevicesAbingdon, Oxfordshire, US
James Noble(Chief Executive Officer)Adrian Rawcliffe(Chief Executive Officer and Director)inGavin Wood(Chief Financial Officer)inWilliam Bertrand(Chief Operating Officer)inJohn Lunger(Chief Patient Supply Officer)inElliot Norry(Chief Medical Officer)in
Co-investorsEight Roads VenturesF-Prime CapitalForesite CapitalNew Enterprise Associates (NEA)Ridgeback Capital
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Executive Officer, Director)DAVID M. TANEN(Executive Officer)FRANZ HUMER(Director)JOHN DEYOUNG(Director)
BoardOWEN WITTE(Director)
Co-investorsForesite CapitalTPGVida VenturesGilead SciencesVVAG Special
Amylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs.
BiotechHealthtechCambridge, US
Justin Klee(Director)inJoshua Cohen(Founder)in
BoardStephen D. Chubb(Director)George M. Milne, PH.D.(Director)
Co-investorsAlpha Wave GlobalBain Capital Life Sciences
Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.
BiotechMedical DevicesSolana Beach, US
Pratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)Sean Jeffries, Ph.D.(Executive Officer)
BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)
Co-investorsQuan CapitalRA CapitalSR One Capital ManagementWestRiver GroupQuan Venture
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAccess BiotechnologyHealthCapNovo HoldingsSofinnova PartnersAvoro VenturesRA Capital
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Executive Officer, Director)inJennifer Doudna(Co-founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in
Co-investorsage1Atlas VentureEcoR1 CapitalForesite CapitalOrbiMedFidelity Investments
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
TROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inTroy E. Wilson(President and Chief Executive Officer, Chairman of the Board)inHEIDI HENSON(Executive Officer)in
Co-investorsARCH Venture PartnersEcoR1 CapitalForesite CapitalNextech InvestOUP (Osage University Partners)ARCH Venture
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAtlas VentureBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures FundNextech Invest+6 more
Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH).
BiotechHealthtechMedical DevicesConshohocken, US
Rebecca Taub(Founder and Director)inMarc R. Schneebaum(Executive Officer)inPaul A. Friedman(Executive Officer, Director)inBill Sibold(President and Chief Executive Officer)inMardi Dier(Executive Vice President and Chief Financial Officer)inCarole Huntsman(Executive Vice President and Chief Commercial Officer)in
Co-investorsBay City CapitalForesite Capital
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Markus Warmuth(M.D., Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)inJohn Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)inPhil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in
Co-investorsAisling CapitalNew Enterprise Associates (NEA)Versant VenturesHBM PartnersAmzak HealthGV (Google Ventures)+1 more
Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.
BiotechHealthtechSan Francisco, US
Cyrus L. Harmon, Ph.D.(Director)Cyrus Harmon(Executive Officer, Director)inCyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)in
Co-investorsBain Capital Life SciencesForesite CapitalLightspeed Venture PartnersRA CapitalBiotechnology Value FundLogos+1 more
Outlook Therapeutics develops ophthalmic therapies for retinal diseases, including anti-VEGF treatments for conditions such as neovascular (wet) age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion.
BiotechHealthtechMedical DevicesIselin, US
Pankaj Mohan(Executive Officer, Director)Lawrence A. Kenyon(Executive Officer, Director)inJeff Evanson(Executive Officer)in
BoardFaisal G. Sukhtian(Director)Yezan Haddadin(Director)Andong Huang(Director)
Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy.
BiotechDeep TechHealthtechBoston, US
Steve Petrou(Co-Founder, President of Research & Development)inKiran Reddy(Executive Officer, Director)inMarcio Souza(President & Chief Executive Officer)in
BoardNicholas G. Galakatos(Director)
Co-investorsCapria VenturesOCV PartnersAlameda ResearchAPOLLO PROJECTSBlackstoneClarus+6 more
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)inJennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)
BoardVijay Pande(Director)in
Co-investorsAndreessen HorowitzOrbiMedMenlo VenturesRA CapitalAvoro Ventures
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies in areas such as metabolic and endocrine disorders.
BiotechHealthtechLongevitySan Diego, US
Brian Lian(President, CEO & Director (Founder))inMichael Morneau(Chief Financial Officer)Dr. Lian(President & Chief Executive Officer, Director)Stephen W. Webster(Director)Matthew W. Foehr(Director)
BoardJ. Matthew Singleton(Director)
Co-investorsLigand Pharmaceuticals
Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders.
BiotechHealthtech
Ian Mortimer(President and Chief Executive Officer)inDarren Cline(Chief Commercial Officer)inAndrea DiFabio(Chief Legal Officer and Corporate Secretary)inJames Empfield(Executive Vice President, Drug Discovery)inTucker Kelly(Chief Financial Officer)inChris Kenney(Chief Medical Officer)in
Co-investorsArcher Capital GroupArcher Venture CapitalForesite CapitalNew Enterprise Associates (NEA)
Ethyreal Bio is a biopharmaceutical company developing medicines for people with Thyroid Eye Disease and Graves' Disease.
BiotechHealthtechCambridge, US
Niranjan Kameswaran(Chief Executive Officer)inJessica Stromme(Chief Development Officer)inKelly Foster(Chief Scientific Officer)inStephen Huang(Senior Vice President, Head of Clinical Development)in
BoardSimon Read(Chairman of the Board and Independent Board Member)in
Co-investorsAtlas VentureMedicxi
Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform.
BiotechDeep TechHealthtech
Co-investorsFrazier Life Sciences
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical DevicesBedminster, US
CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in
Co-investorsAlta PartnersForesite CapitalOUP (Osage University Partners)Sofinnova Ventures
Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease.
BiotechHealthtechMedical Devices
Co-investorsFountain Healthcare PartnersLongitude CapitalSignet Healthcare PartnersSofinnova Ventures
Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions.
BiotechHealthtechCranbury, US
Daphne Quimi(Executive Officer)John Crowley(Executive Officer, Director)William D. Baird, III(Executive Officer)
BoardCraig A. Wheeler(Director)Ted W. Love(Director)inMargaret G. McGlynn(Director)
Co-investorsCanaan PartnersFrazier Life SciencesNew Enterprise Associates (NEA)Prospect Venture Partners
Co-investorsEpidarex CapitalF-Prime CapitalKeyhorse CapitalSofinnova VenturesSolasta VenturesvenBio Partners
The company develops therapies for people with severe autoimmune diseases.
BiotechHealthtechMedical Devices
Co-investorsMPM BioImpactPMV
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in
Co-investorsVivo CapitalAisling CapitalForesite CapitalRA CapitalSofinnova Ventures
Assembly Bio is a biopharmaceutical company developing novel therapeutic candidates for viral and liver diseases, including programs targeting herpesviruses, hepatitis delta virus, hepatitis B virus, and cholestatic liver diseases.
BiotechHealthtechMedical Devices
Jason Okazaki(Chief Executive Officer & President)inWilliam Delaney, PhD(Chief Scientific Officer)Anuj Gaggar, MD, PhD(Chief Medical Officer)
Co-investorsLongitude Capital
BiotechCambridge, US
Mohamed Genead(Executive Officer, Director)inMichael Tolentino(Executive Officer, Director)inDavid Callanan(Executive Officer)inTarek Hassan(Executive Officer)inDerek Kunimoto(Executive Officer)in
BoardDavid Guyer(Director)
Co-investorsCatalio Capital Management, LPJeito CapitalLongitude CapitalOmega Funds
Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases.
BiotechDeep TechHealthtechMedical Devices
Co-investorsBrace PharmaF-Prime CapitalFrazier Life SciencesMoore Venture Partners
Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development.
BiotechHealthtechBaltimore, US
James N. Campbell(President, Chief Scientific Officer)inKerrie L. Brady(Executive Officer)inGregg Beloff(Executive Officer)Jeffrey B. Kindler(Chief Executive Officer)inCharles Oh(Chief Medical Officer)inSmital Shah(Acting CBO)in
Co-investorsCatalio Capital Management, LPEFung CapitalNew Enterprise Associates (NEA)Quan Capital6 Dimensions CapitalExome Asset Management
BiotechHealthtechCambridge, US
Michael R. Cooper(Executive Officer)inJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)inTom Maniatis(Director)
Co-investorsBain Capital Life SciencesVenrockThe Column GroupThird Rock Ventures
Corvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.
BiotechHealthtechBurlingame, US
Richard A. Miller(President & CEO, Co-Founder)inLeiv Lea(Executive Officer)in
BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Co-Founder)inTerry G. Gould(Director)
Co-investorsForesite CapitalOrbiMed
CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology.
BiotechDeep TechHealthtechZug, CH
Emmanuelle Charpentier(Co-founder)Samarth Kulkarni(Chief Executive Officer and Chairman of the Board)inJames R. Kasinger(General Counsel and Secretary)inStephen Kennedy(Head of Technical Operations)inMegan Wherry Menner(Head of Human Resources)inNaimish Patel(Chief Medical Officer)in
Co-investorsNew Enterprise Associates (NEA)AbingworthVersant Ventures
Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.
BiotechHealthtechMedical DevicesNewark, US
Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)
BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)in
Co-investorsBay City CapitalForesite CapitalVantagePoint Capital PartnersAbingworth
Fennec Pharmaceuticals develops treatments for cisplatin-induced hearing loss, a side effect of cancer chemotherapy.
BiotechHealthtechMedical DevicesResearch Triangle Park, US
Krysia Lynes(Executive Officer)Rostislav Raykov(Executive Officer, Director)
BoardAdrian Haigh(Director)Steven Skolsky(Director)Chris Rallis(Director)Khalid Islam(Director)
HedgeServ provides a cloud-based investor services platform for investment managers that automates fund administration tasks including investor onboarding, capital calls, distributions, and reporting.
Cloud ComputingFintechSaaS
Co-investorsGolub Growth
Amgen is a pioneer in biologic medicine development using living cells to create treatments for serious illnesses with limited existing options.
BiotechHealthtech
Co-investorsAtlas VentureNew Enterprise Associates (NEA)
IOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
BiotechMedical Devices
Dr. Dhingra
Co-investorsEIR VenturesKurma PartnersRA CapitalSamsara BioCapitalSunstone CapitalVivo Capital+2 more
Iovance develops TIL (tumor-infiltrating lymphocyte) therapy, a personalized cancer treatment that isolates immune cells from a patient's tumor, expands them in a centralized facility using proprietary manufacturing processes, and returns them for infusion back into the patient.
BiotechHealthtechMedical DevicesPhiladelphia, US
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.
BiotechHealthtechNewton, US
Stuart Poulton(Executive Officer)inMichael Mano(Executive Officer)inReshma Rangwala(Executive Officer)inRichard Paulson(Executive Officer, Director)inStephen Mitchener(Executive Officer)inMichael Mason(Executive Officer)in
Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSRA Capital
Krystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions.
BiotechHealthtechMedical DevicesPittsburgh, US
Suma Krishnan(President, Research & Development)inKrish Krishnan(Chairman & CEO)inDoug Norby(Director)Dino Rossi(Director)
BoardDan Janney(Director)
Co-investorsFrazier Life SciencesAlta Partners
BiotechRadnor, US
Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)
BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)
Co-investorsBain Capital Life SciencesCanaan PartnersConnecticut InnovationsSofinnova VenturesDomain AssociatesFlare Capital Partners+1 more
Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).
BiotechHealthtechCambridge, US
MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)
Co-investorsBain Capital Life SciencesF-Prime CapitalLightstone VenturesNew Enterprise Associates (NEA)Nextech InvestPfizer Venture Investments+1 more
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.
BiotechMedical DevicesUtrecht, NL
Ton Logtenberg(Executive Officer, Director)inMark Throsby(Executive Officer)inHui Liu(Executive Officer)inJohn Crowley(Executive Officer)inL. Andres Sirulnik(Executive Officer)inLex Bakker(Executive Officer)in
Co-investorsPfizer Venture InvestmentsRA CapitalSofinnova Ventures
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut Innovations+4 more
Nuvalent is a biopharmaceutical company that uses chemistry and structure-based drug discovery to design small-molecule kinase inhibitors as precisely targeted cancer therapies.
BiotechHealthtechCambridge, US
Matthew Shair(Director)inHenry Pelish, PhD(Chief Scientific Officer)R. Porter James(Executive Officer, Director)inAlex Balcom(Executive Officer)inJames Porter, PhD(Chief Executive Officer)Alex Balcom, MBA, CPA(Chief Financial Officer)in
Co-investorsBain Capital Life SciencesDeerfield Management Company
Ottimo Pharma is a clinical-stage biotech company developing PD-1/VEGFR2 dual-paratopic antibodies for cancer treatment.
Biotech
Co-investorsOrbiMed
PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function.
BiotechHealthtechCranbury, US
David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Director)
BoardPeter Thompson(Director)inSteve Winick(Director)Arnold Oronsky(Director)
Co-investorsNextech InvestOUP (Osage University Partners)RA CapitalOrbiMedOsage University Partners
Rocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders.
BiotechDigital HealthMedical Devices
Gaurav Shah(Co-founder & Chief Executive Officer)in
BoardRoderick Wong(Director)inNaveen Yalamanchi(Director)in
Co-investorsBroadview VenturesCivilization Ventures Management, LlcRTW Investments L.P.
Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions.
BiotechHealthtechCambridge, US
WILLIAM CIAMBRONE(Executive Officer)DOUGLAS S. INGRAM(Executive Officer, Director)inDAVID TYRONNE HOWTON(Executive Officer)SANDESH MAHATME(Executive Officer)GILMORE O'NEILL(Executive Officer)ALEXANDER CUMBO(Executive Officer)
Co-investorsRoche Venture Fund
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)
Co-investorsAtlas VentureEcoR1 CapitalFrazier Life SciencesNextech InvestVida VenturesAbingworth+3 more
Stemline is an oncology-focused pharmaceutical company developing and commercializing cancer therapies, including ELZONRIS (tagraxofusp-erzs) for blastic plasmacytoid dendritic cell neoplasm and ORSERDU (elacestrant) for ER-positive, HER2-negative, ESR-1 mutated advanced or metastatic breast cancer.
BiotechHealthtechNew York, US
Ivan Bergstein, M.D.(Executive Officer, Director)
BoardRonald Bentsur(Director)
GSK is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients.
BiotechHealthtechLondon, GB
Mary Lynne Hedley(Executive Officer, Director)Leon O. Moulder, Jr.(Executive Officer, Director)Jeffrey Hanke(Executive Officer)Joseph L. Farmer(Executive Officer)inGrant C. Bogle(Executive Officer)Martin H. Huber(Executive Officer)
Co-investorsNew Enterprise Associates (NEA)Kleiner Perkins
BiotechSouth San Francisco, US
Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)
BoardSandra Coufal(Director)David Bonita(Director)inKlaus Veitinger(Director)inRobert Alpern(Director)
Co-investorsLongitude CapitalFrazier Life SciencesHercules Capital, Inc.OrbiMedWellington Management
Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.
BiotechDeep TechHealthtechLongevityChicago, US
Jim Sullivan(CEO)inKevin Hunt(CSO)in
Co-investorsOrbiMedPontifax Venture Capital
AI & Machine LearningBiotechHealthtech
Co-investorsMedicxiTCG CrossoverUniQuest Extension Fund (UEF)venBio Partners
Viveve publishes evidence-based health guides covering six core topics—heart health, women's health, nutrition, hormones, sexual health, and aging—written without pseudoscience or supplement marketing.
Digital HealthHealthtechMedia & EntertainmentWellness & Fitness
Co-investors5AM Ventures
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Co-investorsARCH Venture PartnersCardinal PartnersNextech InvestSoftBank Vision FundVersant Ventures
Whitehawk Therapeutics develops antibody-drug conjugate (ADC) therapeutics through intentional clinical development.
BiotechHealthtech
Dave Lennon, PhD(President & CEO)Dave Lennon(President & CEO)in
Co-investorsInvus
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Acerta PharmaAvadel PharmaceuticalsBellicumCatalystbiosciencesDiceGbtIVERIC BioNantkwestProteostasisSyndaxTherachonTourmaline BioVanqua BioZealand PharmaZogenix
Exits · 21
16 IPOs · 5 acquisitions · showing 20AdaptimmuneOTC: ADAPYAllogene TherapeuticsNASDAQ: ALLOAmylyxNASDAQ: AMLXDesigntxNASDAQ: DSGNHemab TherapeuticsNASDAQ: COAGIntellia TherapeuticsNASDAQ: NTLAKura OncologyNASDAQ: KURAKymera TherapeuticsNASDAQ: KYMRMadrigalNASDAQ: MDGLMonte Rosa TherapeuticsNASDAQ: GLUEOlemaNASDAQ: OLMAOutlook TherapeuticsNASDAQ: OTLKPraxisNASDAQ: PRAXScribe TherapeuticsNASDAQ: SCTXViking TherapeuticsNASDAQ: VKTXXenon PharmaNASDAQ: XENEConstellation Pharmaacq. by NovartisHorizon Therapeuticsacq. by AmgenVicebioacq. by SanofiVividion Therapeuticsacq. by Bayer
Portfolio news
latest coverage across their companiesargenx · investing.com · Sep 14, 2026
Olema · investing.com · Sep 14, 2026
Iovance · investing.com · Sep 14, 2026
Karyopharm · bowtiedbiotech.substack.com · Sep 12, 2026
Viking Therapeutics · finance.yahoo.com · Sep 11, 2026
Madrigal · finance.yahoo.com · Sep 10, 2026
CRISPR · aol.com · Sep 8, 2026
Designtx · defenseworld.net · Sep 2, 2026
Frequently asked questions
- How many investments has Avoro Capital Advisors made?
- Avoro Capital Advisors has 76 tracked investments, 21 of which have exited, including 3 dated in the last 24 months.
- What stage does Avoro Capital Advisors invest at?
- Avoro Capital Advisors invests at the Seed, Series A stages.
- What sectors does Avoro Capital Advisors focus on?
- Avoro Capital Advisors focuses on Biotech, Healthtech.
- Where is Avoro Capital Advisors located?
- Avoro Capital Advisors is headquartered in New York, US.
- Who does Avoro Capital Advisors co-invest with?
- Avoro Capital Advisors most often shares deals with Foresite Capital, New Enterprise Associates (NEA), Sofinnova Ventures, among 82 tracked co-investors.
Co-investors · 10
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Innovation Works is a nonprofit early-stage investor supporting the growth of Southwestern Pennsylvania's tech economy through venture funding, accelerator programs, and ecosystem support.
Riverfront Ventures is an early-stage venture capital fund based in Pittsburgh that invests in early-growth stage technology companies, serving as the venture capital arm of Innovation Works.
Pappas Capital is a life sciences venture capital firm that invests in and helps build companies developing next-generation life science products and technologies.
Firms observed investing alongside Avoro Capital Advisors, from public investor directories. Shared companies are the overlap with Avoro Capital Advisors's recorded portfolio.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.